208.68
0.65%
-1.37
After Hours:
208.68
Penumbra Inc stock is currently priced at $208.68, with a 24-hour trading volume of 343.55K.
It has seen a -0.65% decreased in the last 24 hours and a -6.06% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $210.0 pivot point. If it approaches the $207.1 support level, significant changes may occur.
Penumbra Inc Stock (PEN) Financials Data
Penumbra Inc (PEN) Revenue 2024
PEN reported a revenue (TTM) of $1.06 billion for the quarter ending December 31, 2023, a +24.95% rise year-over-year.
Penumbra Inc (PEN) Net Income 2024
PEN net income (TTM) was $90.95 million for the quarter ending December 31, 2023, a +4,643% increase year-over-year.
Penumbra Inc (PEN) Cash Flow 2024
PEN recorded a free cash flow (TTM) of $82.12 million for the quarter ending December 31, 2023, a +209.55% increase year-over-year.
Penumbra Inc (PEN) Earnings per Share 2024
PEN earnings per share (TTM) was $2.31 for the quarter ending December 31, 2023, a +4,083% growth year-over-year.
Penumbra Inc Stock (PEN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Roberts Johanna | EVP, Gen. Counsel & Secretary |
Apr 01 '24 |
Sale |
217.07 |
600 |
130,242 |
64,281 |
Kassing Don W. | Director |
Apr 01 '24 |
Sale |
223.18 |
170 |
37,941 |
1,175 |
Elsesser Adam | CEO and President |
Mar 06 '24 |
Option Exercise |
7.75 |
5,000 |
38,750 |
5,000 |
Bose Arani | Director |
Mar 04 '24 |
Sale |
250.20 |
7,500 |
1,876,500 |
164,294 |
Kassing Don W. | Director |
Mar 01 '24 |
Sale |
234.72 |
778 |
182,612 |
1,345 |
Roberts Johanna | EVP, Gen. Counsel & Secretary |
Mar 01 '24 |
Sale |
237.68 |
600 |
142,607 |
62,997 |
Grewal Harpreet | Director |
Jan 03 '24 |
Sale |
240.82 |
170 |
40,939 |
8,980 |
Sarna Surbhi | Director |
Jan 02 '24 |
Sale |
247.68 |
85 |
21,053 |
2,295 |
Roberts Johanna | EVP, Gen. Counsel & Secretary |
Dec 27 '23 |
Option Exercise |
22.04 |
2,450 |
53,998 |
63,597 |
Roberts Johanna | EVP, Gen. Counsel & Secretary |
Dec 01 '23 |
Sale |
226.42 |
600 |
135,851 |
62,251 |
Penumbra Inc Stock (PEN) Latest News
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
Benzinga
Here's Why You Should Retain Penumbra (PEN) Stock for Now
Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks Investment Research
Penumbra Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Benzinga
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail
Zacks Investment Research
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Zacks Investment Research
About Penumbra Inc
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Cap:
|
Volume (24h):